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Um procedimento analítico em sistema de análises em fluxo com multicomutação é proposto 
para a determinação de captopril e construção de curvas de dissolução de medicamentos. O 
método é baseado na reação do fármaco com Cu(II), com posterior complexação de Cu(I) com 
4,4’-dicarboxi-2,2’-biquinolina (BQA) e detecção espectrofotométrica. Foi observada resposta 
linear entre 25 e 300 μmol L-1 captopril, com limite de detecção de 7 μmol L-1 (99,7% de confiança). 
O coeficiente de variação (n = 20) e a frequência de amostragem foram 2,2% e 47 determinações 
por hora, respectivamente, com consumo de 290 μg de BQA e geração de 3,6 mL de resíduo 
por determinação. Os resultados para 7 amostras de preparações farmacêuticas concordaram 
com os obtidos pelo procedimento volumétrico de referência com 95% de confiança. Perfis de 
dissolução obtidos com um aparato construído no laboratório foram concordantes com os relatados 
na literatura, com coeficiente de variação de 1,8% para três replicatas do produto de referência.
A flow-based analytical procedure exploiting multicommutation is proposed for captopril 
determination and the construction of dissolution curves. The procedure is based on the 
redox reaction between Cu(II) and the drug with the subsequent complexation of Cu(I) with 
4,4’-dicarboxy-2,2’-bichinoline (BCA) and spectrophotometric detection. A linear response 
was observed between 25 and 300 μmol L-1 captopril and the detection limit was estimated as 
7 μmol L-1 (99.7% confidence level). The coefficient of variation (n = 20) and sampling rate were 
2.2% and 47 determinations per hour, respectively, consuming 290 μg of BCA and generating 
3.6 mL of waste per determination. The results for seven pharmaceutical samples agreed with 
those obtained by the reference volumetric procedure at the 95% confidence level. The dissolution 
profiles attained with a lab-made dissolution apparatus agreed with those reported in the literature, 
with a coefficient of variation of 1.8% for three replicates of the reference product.
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Introduction
Tablets are the most commonly prescribed dosage forms 
of pharmaceuticals due to their wide acceptance by patients, 
the reliability of manufacturing processes and their stability 
in comparison to other forms.1 During the manufacturing 
process, tests must be carried out to ensure the quality of 
tablets, their administration safety and the bioavailability 
of the pharmaceutical compounds.2,3 For this reason, assays 
should mimic in vivo conditions for the dissolution and 
absorption of drugs.
Bioavailability studies of pharmaceuticals became usual 
after the detection of clinical inefficacy and intoxication 
cases resulting from the administration of commercial 
formulations. Apparently harmless changes of excipients 
can alter dissolution profiles of pharmaceutical preparations, 
resulting in toxic plasma levels of the drug.4 The drug 
release evaluation from solid dosage forms is one of the 
most important tests. In these assays, the amount of drug 
dissolved under standardized conditions of temperature, 
liquid/solid interface and medium composition is quantified 
as a function of time.1,5 For this purpose, the analytical 
procedures should consume low sample volumes, present 
a high sampling rate and allow sample processing under 
rigorously controlled experimental conditions.6,7
In general, dissolution assays are performed with 
Apparatus 1 or 2, as recommended by the United States 
Pharmacopoeia (USP) under controlled experimental 
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conditions (e.g., dissolution medium, total testing time 
and sampling time).8,9 These equipments are expensive, 
fragile and require training to use. The results should be 
compared with those obtained using the commercially 
available reference product or its bioequivalent generic.9 
Several works reported the implementation of dissolution 
studies of different drugs in flow-based systems.6,7,10,11 
Flow analysis provides several advantages when coupled 
to dissolution apparatus, namely easy interfacing, high 
sampling rate, real-time monitoring, low cost, simplicity 
and high portability. This process can be adapted to tablets 
with rapid or slow releases, making online derivatization, 
preconcentration, filtration and dilution of the sample 
feasible.3 Flow systems based on multicommutation 
increase system versatility and minimize operational 
costs, analyst intervention, reagent consumption and 
waste generation.12
Captopril, 1-[(2S)-3-mercapto-2-methylpropionyl]-
L-proline, is an angiotensin-converting enzyme (ACE) 
inhibitor widely used for the treatment of arterial 
hypertension and congestive heart failure.11,13 The 
official methods for its determination are based on 
volumetry or chromatography,14 even though several 
alternative procedures have been reported in the literature, 
employing fluorimetry,15 spectrophotometry,13,14,16 
chemiluminescence,17 potentiometry18 and indirect atomic 
absorption spectrometry.19 These methodologies are usually 
time consuming, making the construction of dissolution 
profiles for solid pharmaceutical forms unfeasible.20
The main goal of this work was to develop a 
multicommuted flow-based procedure for captopril 
determination to construct dissolution curves. The 
procedure was based on the redox reaction between Cu(II) 
and captopril, followed by quantification of Cu(I) ions by 
spectrophotometry in the presence of 4,4’-dicarboxy-2,2’-
bichinoline (BCA). Previous works exploited this reaction 
for the determination of proteins in biological materials,21,22 
tannins in beverages23 and uric acid in urine.24
Materials and Methods
Reagents and solutions
All solutions were prepared with deionized water 
(17.9 MΩ cm-1) and analytical grade chemicals. A 
4.0 mmol L-1 CuSO4 solution was prepared in 0.1 mol L-1 
ammonium acetate buffer at pH 7.0 (R1 reagent). The 
R2 reagent was prepared by the dissolution of BCA 
(Na2C20H10N2O4) in water, yielding a 6.0 mmol L-1 
solution. The carrier was a 20 mmol L-1 NH4OH solution. 
Captopril 2.3 mmol L-1 stock solutions were prepared 
daily in 0.01 mol L-1 HCl, which is the dissolution medium 
recommended by the USP.9 The reference solutions were 
prepared by diluting the stock in 0.01 mol L-1 HCl. The 
captopril samples (12.5 or 25 mg) were purchased at local 
drugstores. 
Apparatus
The manifold (Figure 1) was constructed with 
four computer-controlled three-way solenoid valves 
(NResearch), polyethylene tubes (0.7 mm i.d.) and 
an acrylic confluence point. A Pentium 166-MHz 
microcomputer equipped with an electronic interface 
(Advantech Corp., PCL-711S) was employed to control 
the valves and for data acquisition and processing. The 
electric potential and current required to switch on the 
devices (12 V and 100 mA, respectively) were supplied 
by a lab-made electronic interface based on an ULN2803 
integrated circuit. The control software was developed in 
Microsoft Visual BasicTM. Fluid propelling was carried out 
by a peristaltic pump (Ismatec, CP 78017-10) equipped 
with a TygonTM tube. Measurements were taken with a 
spectrophotometer (Micronal, B342II) by using a quartz 
flow-cell (1 cm optical path; 80 μL internal volume). The 
analog output of the spectrophotometer was connected to 
one of the input ports of the interface for data acquisition. 
A pulse dampener was designed with a closed polyethylene 
tube (4 cm long and 1 cm i.d.) to improve the repeatability. 
The device was vertically positioned, with the inlet at the 
top and the outlet at the bottom.
The apparatus employed for the dissolution studies 
(Figure 2A) was designed to simulate the device and 
experimental conditions recommended by the USP.9 This 
Figure 1. Flow diagram of the multicommuted system for captopril 
determination and construction of dissolution curves. S = sample; 
R1 = 4.0 mmol L-1 Cu(II) in NH4Ac buffer (pH 7.0, 0.1 mol L-1); 
R2 = 6.0 mmol L-1 BCA; C = carrier solution (20.0 mmol L-1 NH4OH); 
Vi = three-way solenoid valves; x = confluence point; B = tubular reaction 
coil (100 cm); D = spectrophotometer (562 nm); PD = pulse dampener; 
P = peristaltic pump; W = waste.
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consists of a beaker (a) containing 500 mL of 0.01 mol L-1 
HCl (dissolution medium) under constant magnetic stirring 
(b) and temperature controlled at (37.0 ± 0.5) oC. A relay 
(not represented on the scheme) was employed to turn on 
and off the heater (c) according to the temperature set of 
the thermostat (d).
Procedures
The dissolution curves were obtained with a 
multicommuted flow system (Figure 1) operated according 
to the switching course described in Table 1. Aliquots 
from the dissolution medium were sampled by filling the 
path between the vessel and joint point x (step 1). The 
analytical path was washed by the carrier stream (step 2) 
before the insertion of the sample and reagents. In step 3, 
aliquots of 80 μL of the sample, and 8 μL of each reagent 
were sequentially inserted into the reactor coil, exploiting 
the binary sampling approach12 with 10 sampling cycles 
for solution handling. Mixing occurred by dispersion 
at the interfaces while the sample zone was transported 
through a 100 cm reactor coil, being the complex 
monitored by spectrophotometry at 562 nm. Optimization 
of experimental conditions was carried out in order to 
improve sensitivity and precision, with minimum reagent 
consumption and waste generation. All measurements 
were based on peak height and made in triplicate. The 
dissolution assay was carried out individually with four 
tablets of each sample.
For the dissolution studies, three different materials 
were evaluated to support the tablets (Figure 2B). One of the 
supports was made with a filter paper tied with a polyamide 
string (e). This support was fixed to the thermometer and 
kept fully submerged in the dissolution medium during 
the entire study. The second device was a cellulose ester 
membrane (12.4-kDa porosity, Sigma, D0530), which was 
used as a bag and similarly attached to the thermometer (f). 
Another gadget was made by a polyamide net fixed on a 
metallic ring (g), which was partially submerged maintain 
complete contact between the sample and the dissolution 
medium.
The effect of concomitant species was evaluated by 
considering the excipients found in commercially available 
tablets, namely microcrystalline cellulose, starch, lactose, 
stearic acid, colloidal silicon dioxide, croscarmellose 
sodium and magnesium stearate. Lactose was the only 
water-soluble species tested and its effect was evaluated at a 
concentration 100-fold higher than captopril (7.5 mmol L-1). 
For the other compounds, the suspensions were prepared 
from 0.2 g of the solid in 50 mL of 0.01 mol L-1 HCl in 
order to evaluate their effects on adsorption of the analyte. 
The suspensions were shaken for 15 min and centrifuged 
for 10 min before measurements.
In order to evaluate the accuracy of the proposed 
procedure, fifteen tablets of each sample were weighed 
and finely powdered. An appropriate amount was then 
suspended in 50 mL of 0.01 mol L-1 HCl so that the final 
captopril concentration was 7.5 mmol L-1 according to the 
values on the label. These suspensions were kept under 
constant stirring for 15 min and then centrifuged for 10 min. 
Measurements were carried out with the supernatant.
Figure 2. (A) Apparatus for dissolution studies. (a) recipient containing the 
dissolution medium (0.01 mol L-1 HCl); (b) magnetic stirrer; (c) heating 
device with thermostat (d) set to (37.0 ± 0.5) oC; (B) tablet supports 
evaluated. (e) filter paper tied with polyamide string; (f) dialysis membrane 
with both borders tied with polyamide string; (g) polyamide net fixed on 
a metallic ring, which was supported at the edge of dissolution medium 
container.
Table 1. Valves switching sequence for captopril determinationa
Step Description V1 V2 V3 V4 time (s)
1 Sampling 1 0 0 1 3.3
2 Analytical path washing 0 0 0 0 30.0
1 0 0 1 2.0
3 Sample and reagent insertionb 0 1 0 1 0.2
0 0 1 1 0.2
4 Transport of sample zone and measurement 0 0 0 0 160.0
aNumbers 0 and 1 indicate that the valves are switched off or on, respectively; bStep 3 was repeated 10 times (10 sampling cycles).
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The iodimetric procedure recommended by the USP9 
was used as the reference for sample analyses. It is based 
on the titration of captopril in an acidic medium containing 
excess of iodide with iodate as the titrant and starch as the 
indicator.
Results and Discussion
The sulfhydryl group bonded to molecules such as 
captopril can reduce copper(II) ions (reaction 1), and 
Cu(I) reacts with BCA (reaction 2) to yield a stable purple 
complex.25 The analyte concentration can be then indirectly 
determined by spectrophotometry.
2 Cu2+ + 2 C8H14O3NC–SH → 2 Cu+ + (C8H14O3NC–S–)2  + 2 H+  (1)
2 BCA2− + Cu+  [Cu(BCA)2]3−  (2)
System optimization
The multicommuted flow system showed in Figure 1 
was employed for captopril determination and construction 
of the dissolution curves. A summary of the ranges of 
variables studied in the optimization step and the selected 
values is presented in Table 2. 
The concentration and volume of the Cu(II) solution 
were critical for the development of the flow-based 
analytical procedure. Although an excess of the metal ion 
is required, formation of the green insoluble salt Cu(BCA) 
can lead to solid deposition in the reactor and flow cell, 
thus causing memory effects and baseline drift.24 The 
analytical signal increased with the Cu(II) concentration up 
to 4.0 mmol L-1. For higher Cu(II) concentrations, the blank 
signal increased about 135 times in view of precipitation. 
The analytical signal reached a plateau from 8 μL of R1 
without significant variation of the blank value. In order to 
avoid the formation of Cu(BCA) during the sampling step, 
the Cu(II) solution was prepared in 0.1 mol L-1 ammonium 
acetate medium at pH 7.0, which provided acetate ions 
and a low concentration of free ammonia yielding stable 
complexes with Cu(II).24 In addition, a NH4OH solution was 
used as carrier to avoid solid deposition in the analytical 
path. This strategy was previously employed in the flow 
systems for tannin23 and uric acid24 determinations, and 
successfully overcame this drawback. In this work, the 
baseline drift was evaluated through 100 measurements 
using different NH4OH concentrations. Baseline drift 
measured as absorbance was 0.030 with 7.5 mmol L-1 
NH4OH and negligible with 20.0 mmol L-1, which was 
selected for further studies.
The volume and concentration of BCA were 
optimized to guarantee reagent excess with minimum 
consumption. The volume of the complexing solution 
did not affect significantly the analytical or blank signals. 
Absorbance values increased with BCA concentration up to 
6.0 mmol L-1, without affecting the magnitude of the blank. 
In order to minimize sample dispersion, the sample volume 
was varied from 40 to 140 μL. The effect was significant 
up to 125 μL; however for a sample volume of 80 μL, 75% 
of the steady state signal was achieved, ensuring a 6-fold 
excess of copper and a lower washing time.
Variation of pH from 6.0 to 8.0 did not affect the 
analytical response significantly and pH 7.0 was chosen due 
to buffering capacity of NH4Ac. These results agreed with 
the obtained in a previous work,24 in which the variation 
of pH in the same range was not critical for copper redox 
reaction and formation of [Cu(BCA)2]3–.
The analytical signal increases with the number of 
sampling cycles due to the effect of the total volume on the 
dispersion of the sample zone.12 The effect of this parameter 
was evaluated by reducing sample and reagent volumes by 
half (R1 = R2 = 4 μL; sample = 40 μL) in order to improve 
mixing at the interfaces. The effect was significant for up 
to 10 sampling cycles yielding an analytical signal 10-fold 
higher than that achieved with one sampling cycle. The 
reactor coil length, which affects both residence time and 
sample dispersion, was fixed at 100 cm as a compromise. 
By considering the total sample zone volume (480 μL) 
and the reactor volume (500 μL), the measurements were 
carried out close to the infinite volume condition (dispersion 
coefficient close to 1).
The flow rate was evaluated from 1.5 to 3.0 mL min-1 
and 2.5 mL min-1 was selected due to the difference between 
Table 2. Ranges of the studied variables and optimized conditions for 
captopril determination
Variable Range 
studied
Selected 
value
R1 volume (μL) 4-20 8
R2 volume (μL) 4-20 8
Sample volume (μL) 40-140 80
Sampling cycles 1-10 10
Cu(II) concentration (mmol L-1) 0.5-8.0 4.0
BCA concentration (mmol L-1) 4.0-10.0 6.0
Reactor length (cm) 50-200 100
Flow rate (mL min-1) 1.5-3.0 2.5
NH4Ac buffer concentration (mol L-1) 0.2-0.7 0.6
NH4Ac buffer pH 6.0-8.0 7.0
NH4OH concentration (mmol L-1) 5.0-20.0 20.0
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the analytical and blank signals. For this flow rate, the 
sample residence time was estimated as 12 s.
Analytical features and application
A calibration curve was constructed (Figure 3) within 
the range 25 to 300 μmol L-1, which showed a linear relation 
between absorbance (A) and captopril concentration 
(c, μmol L-1), represented by the equation A = −3.40×10-2 
+ 3.20×103 c (r = 0.999). The detection limit was estimated 
as 7 μmol L-1 (99.7% confidence level) and the repeatability 
was evaluated with a 120 μmol L-1 captopril reference 
solution, yielding a coefficient of variation of 2.2% 
(n = 20). The consumptions of copper sulfate and BCA 
were estimated as 80 μg and 290 μg, respectively, which 
generated 3.6 mL of waste per determination. The unit cost 
was estimated as US$ 0.03.
The effect of the execipients commonly present in 
captopril formulations was evaluated. The analytical signal 
variations were lower than 5% for concomitant amounts 
higher than those expected in pharmaceutical preparations.
The samples were analyzed by the proposed and 
reference9 procedures and the results are shown in Table 3. 
The results obtained by both methodologies agreed at 
the 95% confidence level. Besides this, the developed 
procedure showed advantages over the reference one,9 
such as a higher sample throughput and 85% lower waste 
generation.
Dissolution studies
For the dissolution studies, three types of tablet supports 
were compared as schematically shown in Figure 2, being 
the results presented in Figure 4. The best results were 
obtained with the polyamide net (Figure 4a). The time 
required to reach the dissolution plateau was longer for the 
cellulose ester membrane (Figure 4b) and the filter paper 
(Figure 4c) because the process was limited by diffusion 
of the analyte through the material instead of by the rate of 
dissolution. The process was slowest for the filter paper and 
the concentration increased linearly with time. The supports 
constructed with filter paper and the cellulose membrane 
could be used to detect differences between samples 
and unconformities in relation to the reference product. 
However, the polyamide net support was selected for the 
dissolution studies to avoid the dependence on diffusion 
and to maintain concordance with the standard procedures 
recommended by the Pharmacopoeias.9,26
Transient signals obtained with the proposed system 
are shown in Figure 5 as well as three dissolution curves 
for the reference pharmaceutical formulation. The results 
were highly reproducible, indicating that the proposed 
system is suitable for the real-time monitoring of drug 
dissolution. The obtained dissolution curves of captopril 
Figure 3. Transient analytical signals for captopril reference solutions 
measured in triplicate. Numbers at the top of peaks indicate concentrations 
in μmol L-1. The inset shows the correspondent calibration curve.
Table 3. Mean values and uncertainties (n = 3) for captopril determination 
by proposed and reference procedures
Sample Proposed procedure 
(mg per tablet)
Reference procedure9 
(mg per tablet)
1 10.5 ± 0.2 11.3 ± 0.1
2 11.5 ± 0.2 12.1 ± 0.1
3 11.3 ± 0.2 11.7 ± 0.1
4 22.2 ± 0.1 23.4 ± 0.1
5 23.5 ± 0.1 23.9 ± 0.1
6 23.6 ± 0.3 23.4 ± 0.1
7 26.5 ± 0.2 24.4 ± 0.1
Figure 4. Dissolution curves obtained with three different tablet supports: 
(a) polyamide net; (b) cellulose ester membrane; (c) filter paper.
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samples presented profiles in agreement with those obtained 
in previous works.20,27 The time for complete solubilization 
was estimated as 7.4 min, which is close to that reported 
by Tomšů et al.20 (7.2 min) who used a commercially 
available dissolution apparatus. For the other samples, the 
mean concentration values presented in Figure 6 show a 
striking difference between the dissolution profile of sample 
1 in relation to samples 2 and 3 (Figure 6A). It should be 
emphasized that the latter depicts the reference product. In 
the case of formulations containing 25 mg (Figure 6B), a 
slight difference was observed between sample 6 and the 
other samples. The differences in the rate of dissolution 
are due to the presence of the excipient croscarmellose, 
found only in samples 1 and 6. The mean times required 
for complete dissolution were 22.1 (sample 1), 7.3-7.5 
(samples 2-4), 5.9 (sample 5), 12.4 (sample 6) and 5.8 
(sample 7). It is important to note that, according to the 
USP, at least 80% of labeled amount of captopril should be 
dissolved in 20 min.9 Although all of the analyzed samples 
met this requirement, the dissolution profiles of some 
samples were quite different from the reference preparation, 
which could result in different in vivo performances.
In comparison to the proposed procedure, the 
chromatographic method developed by Azevedo and co-
workers27 is time consuming (5 min per measurement), 
which is a drawback for dissolution studies. Besides 
this, a high amount of toxic waste was generated due to 
the use of methanol in the mobile phase (ca. 3 mL per 
determination) and the aliquots of dissolution medium 
containing the dissolved drug were collected manually, 
increasing the susceptibility to errors. Another procedure 
for the construction of dissolution profiles exploited a flow 
system with derivative spectrophotometry.20 Mathematical 
data treatment is required to correct interference from 
concomitant species. The proposed procedure is an 
alternative to these studies due to its good accuracy and 
precision, high sampling rate, as well as low reagent 
consumption and waste generation. The quantification 
limit is suitable for measurements at the initial stages 
of the dissolution curves while samples containing 
higher amounts of the drug can be diluted online24,28 for 
measurements during the final stages.
Conclusions
This work describes a multicommuted flow-based 
analytical procedure for captopril determination which 
exploits the reduction of Cu(II) by the sulfhydryl groups 
of the drug, followed by complexation with BCA and 
spectrophotometric quantification. The developed procedure 
presents favorable analytical features such as improved 
precision and low reagent and sample consumption, 
which are extremely important for experiments involving 
Figure 5. Dissolution curves for reference captopril tablets with the lab-
made dissolution system showed in Figure 2. The inset shows transient 
analytical signals for one sample.
Figure 6. Average concentrations (n = 4) determined in dissolution 
experiments for captopril samples containing (A) 12.5 mg and (B) 25 mg 
per tablet.
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quality control of pharmaceutical preparations, including 
dissolution studies. The results of captopril determination 
in commercial samples agreed with those obtained by 
the time-consuming reference volumetric procedure. For 
dissolution curves construction, three different sample 
supports were evaluated; the polyamide net was chosen 
because the process was not limited by diffusion of the 
dissolved drug. The proposed procedure was effective at 
detecting nonconformities for some samples that presented 
different dissolution profiles and thus time to achieve the 
steady state condition. The lab-made apparatus is then 
very suitable for dissolution studies of pharmaceutical 
preparations due to the high repeatability between 
replicates, agreement with results reported in the literature 
and the low cost of the devices. 
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